Biofrontera revised earnings guidance for the year 2019. The preliminary, unaudited turnover of the Biofrontera Group for the period 1 January to 31 December 2019 was between EUR 31.1 million and EUR 31.4 million, slightly above the last guidance. This corresponds to a sales growth of almost 50% compared to the previous year, with pure product sales increasing by approximately 46%. Preliminary revenues from product sales in the USA are expected to be around EUR 23.3 million, compared to EUR 14.9 million in the same period of 2018 (ca. +57%). In Germany, revenues from product sales will amount to approx. EUR 4.6 million, compared with EUR 3.3 million for the full year 2018 (ca. +40%). Revenues for Europe excluding Germany were roughly on par with the previous year, with rising revenues in Spain and the United Kingdom offsetting lower revenues with license partners.